ID: ALA426859

Max Phase: Preclinical

Molecular Formula: C31H36N4O6

Molecular Weight: 560.65

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2ccc3[nH]ccc3c2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C31H36N4O6/c1-5-6-12-24(25(36)27(37)33-19(2)20-10-8-7-9-11-20)34-30(40)41-26-29(39)35(18-31(26,3)4)28(38)22-13-14-23-21(17-22)15-16-32-23/h7-11,13-17,19,24,26,32H,5-6,12,18H2,1-4H3,(H,33,37)(H,34,40)/t19-,24+,26-/m1/s1

Standard InChI Key:  MZPXGBOXSJSLGE-YZXAJQSBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 560.65

Molecular Weight (Monoisotopic): 560.2635

AlogP: 4.28

#Rotatable Bonds: 10

Polar Surface Area: 137.67

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.24

CX Basic pKa:

CX LogP: 5.03

CX LogD: 5.03

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.25

Np Likeness Score: -0.30

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature